Liberum Capital restated their hold rating on shares of Cello Health (LON:CLL) in a research report report published on Wednesday, ThisIsMoney.Co.Uk reports.

Separately, FinnCap reissued a corporate rating on shares of Cello Health in a research note on Friday, January 17th.

CLL traded up GBX 2 ($0.03) during trading on Wednesday, reaching GBX 106.50 ($1.40). The company had a trading volume of 48,219 shares, compared to its average volume of 46,452. The firm’s 50-day simple moving average is GBX 134.14 and its 200 day simple moving average is GBX 131.52. The company has a market cap of $111.11 million and a price-to-earnings ratio of 17.46. Cello Health has a 12-month low of GBX 111 ($1.46) and a 12-month high of GBX 150 ($1.97). The company has a debt-to-equity ratio of 4.70, a quick ratio of 1.23 and a current ratio of 1.28.

The business also recently declared a dividend, which will be paid on Friday, May 22nd. Investors of record on Thursday, April 23rd will be paid a GBX 2.95 ($0.04) dividend. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a yield of 2.85%. This is a boost from Cello Health’s previous dividend of $1.15. Cello Health’s dividend payout ratio (DPR) is currently 0.66%.

Cello Health Company Profile

Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.

Recommended Story: What is the definition of a trade war?

Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with's FREE daily email newsletter.